

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5467182

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
KELEXSYN, INC.	07/01/2016
RECEIVING PARTY DATA	
Name:	G1 THERAPEUTICS, INC.
Street Address:	79 TW ALEXANDER DRIVE
City:	RESEARCH PARK TRIANGLE
State/Country:	NORTH CAROLINA
Postal Code:	27709
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16230381
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6786941262
Email:	docket@kipsllc.com
Correspondent Name:	KNOWLES INTELLECTUAL PROPERTY STRATEGIES, LLC
Address Line 1:	400 PERIMETER CENTER TERRACE
Address Line 2:	SUITE 200
Address Line 4:	ATLANTA, GEORGIA 30346
ATTORNEY DOCKET NUMBER:	12024-035WO1US1 (2)
NAME OF SUBMITTER:	BRENT R. BELLOWS
SIGNATURE:	/Brent R. Bellows/
DATE SIGNED:	04/10/2019
Total Attachments: 2	
source=12024-035P1_2016-07-01_Executed Assignments Kalexsyn-G1#page1.tif	
source=12024-035P1_2016-07-01_Executed Assignments Kalexsyn-G1#page2.tif	

ASSIGNMENT

WHEREAS, **Kalexsyn, Inc.**, a corporation of the State of Michigan, having its principal place of business at 4502 Campus Drive, Kalamazoo, Michigan 49008 (hereinafter "ASSIGNOR"), owns certain inventions and improvements disclosed in a provisional patent application titled "**SYNTHESIS OF N-(HETEROARYL)-PYRROLO [3,2-D] PYRIMIDIN-2-AMINES**" filed in the United States Patent and Trademark Office on **July 1, 2016** and assigned Provisional Application No. **62/357,797**; (collectively "Application") and for which an application for Letters Patent in the United States and other foreign jurisdictions claiming priority to the said provisional application will be made.

WHEREAS, **G1 Therapeutics, Inc.**, a corporation of the State of North Carolina, having a place of business at 79 TW Alexander Drive, 4501 Research Commons, Suite 100, Research Triangle Park, North Carolina, 27709 (hereinafter, "ASSIGNEE"), is desirous of acquiring an interest in the same;


NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR by these presents does sell, assign and transfer to ASSIGNEE the full, exclusive and entire right, title, and interest in the full, exclusive, and entire right, title, and interest in and to said provisional application, and in and to all inventions and improvements disclosed and described in said provisional application;

For the same consideration, ASSIGNOR, by these presents, does sell, assign, and transfer to ASSIGNEE, the full, exclusive, and entire right, title, and interest in and to any U.S. nonprovisional or foreign application or applications corresponding to said provisional application, in whole or in part, and to any Letters Patent and similar protective rights granted on said U.S. nonprovisional or foreign applications, and in and to the right to claim any applicable priority rights arising from or required for said U.S. nonprovisional or foreign applications under the terms of any applicable conventions, treaties, statutes, or regulations; said U.S. nonprovisional or foreign applications to be filed and issued in the name of ASSIGNEE, or its designee insofar as permitted by applicable law;


AND, for the same consideration, ASSIGNOR agree to sign all lawful papers, execute all nonprovisional applications and other applications, make all assignments and rightful oaths, and generally do everything possible to aid ASSIGNEE, its successors, assigns, and nominees to obtain and enforce proper protection for all said inventions and improvements in all countries throughout the world.

The Assignor agrees that this general assignment is effective from the 1st day of July 2016.

IN TESTIMONY, WHEREOF, the Assignor and Assignee set hereunto their hands and seal this date.



**Authorized Signatory
For Kalexsyn, Inc.**



**Authorized Signatory
G1 Therapeutics, Inc.**